Their study demonstrated for the first time that prostate cancer cells express NPRA and NPRC, suggesting that hormones act through the receptor-mediated signaling pathway, and providing experimental evidence for the development of novel prostate cancer targeted therapies based on the hormonally active peptides of the ANP gene, especially the effects of vasodilator and ANP, on prostate tumor cells. The gene discussed is NPR3; the disease is prostate carcinoma.